Scilex Holding Co. Files 8-K for Material Definitive Agreement

Ticker: SCLXW · Form: 8-K · Filed: Oct 7, 2024 · CIK: 1820190

Scilex Holding Co 8-K Filing Summary
FieldDetail
CompanyScilex Holding Co (SCLXW)
Form Type8-K
Filed DateOct 7, 2024
Risk Levelmedium
Pages2
Reading Time3 min
Key Dollar Amounts$0.0001, $11.50, $2,000,000, $1,700,000, $300,000
Sentimentneutral

Sentiment: neutral

Topics: material-agreement, sec-filing, 8-k

TL;DR

Scilex Holding Co. signed a big deal on Oct 2nd, filed it with the SEC today.

AI Summary

On October 2, 2024, Scilex Holding Co. entered into a material definitive agreement. The company, incorporated in Delaware, filed an 8-K report with the SEC on October 7, 2024, detailing this agreement and related financial statements and exhibits.

Why It Matters

This filing indicates a significant new contract or partnership for Scilex Holding Co., which could impact its future business operations and financial performance.

Risk Assessment

Risk Level: medium — Entering into material definitive agreements can introduce new risks and opportunities, the specifics of which are not detailed in this initial filing.

Key Players & Entities

  • Scilex Holding Co. (company) — Registrant
  • October 2, 2024 (date) — Date of earliest event reported
  • October 7, 2024 (date) — Date of report filing
  • Delaware (jurisdiction) — State of incorporation

FAQ

What is the nature of the material definitive agreement entered into by Scilex Holding Co. on October 2, 2024?

The filing states that an "Entry into a Material Definitive Agreement" is an item of disclosure, but the specific details of the agreement are not provided in the provided text.

When did Scilex Holding Co. file this 8-K report?

Scilex Holding Co. filed this 8-K report on October 7, 2024.

What is Scilex Holding Co.'s state of incorporation?

Scilex Holding Co. is incorporated in Delaware.

What is the primary business of Scilex Holding Co. according to the filing?

The filing categorizes Scilex Holding Co. under "BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]".

What is the Commission File Number for Scilex Holding Co.?

The Commission File Number for Scilex Holding Co. is 001-39852.

Filing Stats: 641 words · 3 min read · ~2 pages · Grade level 12.4 · Accepted 2024-10-07 17:24:33

Key Financial Figures

  • $0.0001 — ich registered Common stock, par value $0.0001 per share SCLX The Nasdaq Stock Mar
  • $11.50 — mon stock, each at an exercise price of $11.50 per share SCLXW The Nasdaq Stock Ma
  • $2,000,000 — ich the Company agreed to pay to Oramed $2,000,000 (the " Specified September Payment ") o
  • $1,700,000 — ayment shall be applied as follows: (i) $1,700,000 of such payment shall be applied to the
  • $300,000 — he A Note on the March 21, 2025 and (y) $300,000 of such payment to purchase the Purchas

Filing Documents

Financial Statements and Exhibits

Financial Statements and Exhibits. (d) Exhibits. Exhibit Number Description 10.1 Consent and Side Letter, dated October 2, 2024, by and between Scilex Holding Company and Oramed Pharmaceuticals, Inc. 104 Cover Page Interactive Data File, formatted in Inline Extensible Business Reporting Language (iXBRL).

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. SCILEX HOLDING COMPANY By: /s/ Jaisim Shah Name: Jaisim Shah Title: Chief Executive Officer and President Date: October 7, 2024

View Full Filing

View this 8-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.